conversion semaglutide to tirzepatide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are tirzepatide semaglutide dose conversion dosing

It targets a different appetite pathway than GLP-1 drugs, which is exactly why the combination works

Results are gradual and closely tied to dose escalation, adherence, and lifestyle factors

When to consider a dose increase A genuine plateau means weight loss has stopped for at least 3-4 consecutive weeks despite consistent dosing, adherence to a moderate caloric deficit, and no changes in medication or health status that could explain the stall

Reduce the damaging impact of fatty liver illness on cells A lack of antioxidants might worsen hepatic cell death and result in fatty liver

You should also be aware of potential side effects and precautions to take for safe, effective results